Published Paper Details:

Sleep disorders, including insomnia, sleep apnea, and narcolepsy, pose significant challenges to public health, affecting millions worldwide. The neuropharmacology of these disorders involves a complex interplay of neurotransmitters, neuropeptides, and neuroanatomical structures that regulate sleep and wakefulness. Key neurotransmitters such as gamma-aminobutyric acid (GABA), serotonin, norepinephrine, and acetylcholine play crucial roles in the initiation and maintenance of sleep. Additionally, the orexin/hypocretin system is increasingly recognized for its role in sleep-wake regulation and the pathophysiology of disorders like narcolepsy. Current pharmacological treatments for sleep disorders include sedative-hypnotics, such as benzodiazepines and non-benzodiazepine sleep aids, which primarily enhance GABAergic activity to promote sleep. Conversely, wakefulness-promoting agents, like modafinil, act on dopamine and norepinephrine systems to improve alertness in conditions such as narcolepsy and excessive daytime sleepiness. Emerging therapies, including orexin receptor antagonists and melatonin receptor agonists, offer novel mechanisms of action aimed at restoring normal sleep patterns without the adverse effects associated with traditional medications. Personalized approaches to treatment, considering individual differences in neurobiology and pharmacokinetics, are essential for optimizing therapeutic outcomes. Furthermore, ongoing research into the neurobiological mechanisms underlying sleep disorders is crucial for developing innovative interventions that target specific pathways involved in sleep regulation.A comprehensive understanding of the neuropharmacology of sleep disorders will facilitate the advancement of effective treatments, ultimately improving sleep quality and overall health in affected individuals.